文献速递治疗药物监测与药物基因组学

伊马替尼、舒尼替尼与帕唑帕尼在癌症患者中的剂量优化

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
PubMed 文献 · Br J Clin Pharmacol · 2017-07-04

该队列研究纳入109例接受伊马替尼、舒尼替尼或帕唑帕尼治疗的患者,共测定396次谷浓度。标准剂量下仅38%患者谷浓度在目标范围内,基于治疗药物监测调整剂量后,41例中35例(85%)达到合适谷浓度,最终全队列64%达到合适谷浓度。

要点

  • 标准剂量下仅38%患者谷浓度达标,52%低于、10%高于目标范围。
  • 基于谷浓度调整剂量后,85%(35/41)患者达到合适谷浓度。
  • 全队列最终64%患者达到合适谷浓度,较基线38%明显提高。

核心结论

  • 剂量优化可有效帮助伊马替尼、舒尼替尼和帕唑帕尼治疗患者达到合适谷浓度。
  • 合适谷浓度患者比例从38%提高至64%。

研究设计与样本

  • 在2012年8月至2016年4月期间开展队列研究,纳入接受伊马替尼、舒尼替尼或帕唑帕尼治疗且进行随访药物浓度监测的患者。
  • 共109例患者,测定396次谷浓度,每例患者中位采样频率为3次。
  • 采用高效液相色谱-串联质谱法测定药物浓度,并用预设算法估算谷浓度。

主要发现

  • 首次测定时,仅38%患者谷浓度在预设目标范围内,52%低于目标范围,10%高于目标范围。
  • 41例接受剂量干预的患者中,35例(85%)达到合适谷浓度。
  • 最终全队列64%患者达到合适谷浓度。

临床怎么用

  • 对接受伊马替尼、舒尼替尼或帕唑帕尼治疗的患者,可基于谷浓度监测结果进行剂量优化以提高达标率。
  • 治疗药物监测可能有助于改善疗效、降低毒性和费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of this study was to monitor how many patients reached adequate trough levels after therapeutic drug monitoring-based dose optimization in daily practice. METHODS: A cohort study was performed in patients treated with imatinib, sunitinib or pazopanib of whom follow-up drug levels were measured between August 2012 and April 2016. Patients' characteristics were collected by reviewing electronic patient records. Drug levels were measured using high-performance liquid chromatography coupled with tandem mass spectrometry and trough levels were estimated using a predefined algorithm. Dose interventions were proposed based on trough levels. RESULTS: In total, 396 trough levels were determined in 109 patients. Median sample frequency per patient was 3. During the first measurement only 38% of patients showed trough levels within the predefined target ranges despite standard dosing; 52% of the patients showed drug levels below and 10% above the target range. In 35 out of 41 patients (85%) dose interventions led to adequate trough levels. Eventually, 64% of the total cohort reached adequate trough levels. CONCLUSIONS: Dose optimization proved an effective tool to reach adequate trough levels in patients treated with imatinib, sunitinib and pazopanib. The percentage of patients with adequate trough levels increased from 38 to 64%. Therapeutic drug monitoring may add to the improvement of efficacy and reduction of toxicity and costs of these treatments.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lankheet NAG, Desar IME, Mulder SF, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017. PMID: 28500677. doi:10.1111/bcp.13327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。